Therapeutic Education Strategy for Patients With Acute Heart Failure (EduStra-HF)

February 26, 2024 updated by: Pr Ariel Cohen, Resicard

Impact of an Intensive Therapeutic Education on Occurrence of Clinical Events in Patients With Acute Heart Failure: EduStra-HF Study

The EduStra-HF study will examine the impact of an intensive therapeutic education on patients discharged from hospital after an episode of acute heart failure (HF).

Patients will be randomized into two groups: one will receive "usual care" monitoring and one will receive a specific educational monitoring programme for 1 year.

All patients will meet with a specialized therapeutic education nurse before discharge.

The effect of the intensive education on HF rehospitalization and quality of life will be examined.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

The prevalence of HF in France is increasing. According to a report from the Haute Autorité de Santé (HAS) - the French Health Authority - published in June 2015 concerning discharge of patients hospitalized for HF, 2.3% of the French adult population is affected. Despite improvements in treatment and HF-specific care, the rehospitalization rate for HF remains substantial, and HF management is a major public health issue.

Chronic HF leads to psychological and physiological issues in patients. Furthermore, this disease affects patient quality of life and activities of daily living.

The HAS also reported that even if iterative hospitalizations are the consequence of complicated and multifactorial situations, some could be prevented by improved patient care.

The aim of the EduStra-HF study is to examine the effect of an intensive therapeutic education on patients discharged from hospital after an episode of acute HF. It will study whether this intervention reduces the rate of rehospitalization and increases quality of life in this population.

To achieve this goal, a multicentre, randomized, two parallel arm study will be conducted. Patients will be included in several cardiology centres in Paris (Ile-de-France) over 2 years and 3 months.

Included patients, chosen from patients admitted for acute HF in the participating hospitals, will be randomized into two groups, which will determine the monitoring they receive after discharge. For each patient, monitoring will last for 1 year from the day they return home.

The first group of patients will be randomized to receive "usual care" monitoring and will not be given specific therapeutic education after discharge.

The second group (intervention arm) will receive a specific educational monitoring programme from nurses via telephone calls and home visits, for 1 year. Monitoring will began early after discharge. Annual medical monitoring and visits to the cardiologist will also be planned.

All patients, regardless of attribution arm, will meet a nurse trained in therapeutic education during their stay in hospital. Moreover, validated and HF-related self-assessed questionnaires will be analyzed to assess quality of life and impact of HF on patient activities of daily living.

In the interventional arm, patients will receive monitoring documents, such as a HF information booklet and a personal monitoring agenda.

The EduStra-HF study will provide a specific analysis of a multisupport therapeutic education (including medical monitoring). Data on all HF drug treatments, including the more recent ones (e.g. Entresto), blood tests results, and cardiologic data will be recorded.

Study Type

Interventional

Enrollment (Actual)

318

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Neuilly-sur-Seine, France, 92200
        • Clinique Ambroise Pare
      • Paris, France, 75014
        • Institut Mutualiste Montsouris
      • Paris, France, 75011
        • Clinique du Mont Louis
      • Paris, France, 75012
        • Hopital AP-HP Saint-Antoine
      • Saint Denis, France, 93200
        • Centre Cardiologique du Nord
      • Versailles, France, 78000
        • Centre Hospitalier André Mignot

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Adult patient with acute HF
  • Affiliated to the French Social Security system
  • Accepting the principle of telephone monitoring
  • Accepting home visits from a study nurse
  • Possession of a mobile phone

Exclusion Criteria:

Psychosocial:

  • Refusal to accept the study design
  • Patient under guardianship
  • Monitoring obstacle: language, cognitive deficiency, itinerant lifestyle, regular travel, institutionalization
  • Inability to sign the consent form or to complete questionnaires

Medical:

  • Active cancer
  • Severe psychiatric or neurological disorder
  • Complicated acute myocardial infarction
  • Significant valvular diseases requiring surgery
  • Hypertrophic obstructive cardiomyopathy
  • Planned heart transplant
  • Cardiac surgery in the previous 3 months
  • Enrollment in another clinical trial
  • Medical or surgical procedure which might interfere with monitoring

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: "Usual care"
Patients will attend an appointment with the therapeutic education nurse before discharge, after which they will have no further contact with the education team. The Research team members will telephone the patient three times during the year (after 2, 6 and 12 months) to collect data on HF treatments, blood tests results, health-related events and hospitalizations.
Experimental: Interventional

Before discharge, patients will attend an appointment with a nurse trained in therapeutic education, in which the nurse will evaluate the overall knowledge and the skills of the patient about HF. The nurse will then define specific educational objectives with the patient, based on the patient's medical history, state of disease, comorbidities, alarm signs, fears and knowledge.

Each patient will receive six telephone calls and two home-visits during the 1 year of follow-up. Each contact between the nurse and the patient will be dedicated to HF education. The patient will also receive regular short text messages containing health advice and appointment reminders.

To help the patient regain his/her autonomy, intervals between education sessions will be progressively longer.

Interventional arm

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of rehospitalizations for acute heart failure (HF) in both groups of patients
Time Frame: 1 year
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patients knowledge about the illness
Time Frame: 1 year
Nurses will evaluate during each telephone call and home visit patients knowledge and skills about the following items : illness, treatments, diet, physical activity, medical follow-up. This data will be recorded in a specific table and classified into "acquired / partially acquired / not acquired" items.
1 year
Global quality of life
Time Frame: 1 year
Assessed by validated questionnaire SF-12
1 year
Quality of life linked to Heart Failure
Time Frame: 1 year
Assessed by validated questionnaire KCCQ-15
1 year
Length of stay for HF and all-cause hospitalizations
Time Frame: 1 year of follow-up
1 year of follow-up
Hospitalization rate for cardiovascular diseases except HF
Time Frame: 1 year of follow-up
1 year of follow-up
Cardiovascular and all-cause mortality rate
Time Frame: 1 year of follow-up
1 year of follow-up
B-type natriuretic peptide (BNP) or NT pro-BNP levels
Time Frame: During 1 year of follow-up
During 1 year of follow-up

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Cost effectiveness of the intervention
Time Frame: During 1 year of follow-up
Comparison between both groups of patients of the HF-hospitalizations average cost, related to the operating cost of the EduStra-HF method.
During 1 year of follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Ariel Cohen, MD PhD, Hopital Saint-Antoine

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 1, 2017

Primary Completion (Actual)

December 30, 2023

Study Completion (Estimated)

September 30, 2024

Study Registration Dates

First Submitted

December 5, 2016

First Submitted That Met QC Criteria

January 25, 2017

First Posted (Estimated)

January 27, 2017

Study Record Updates

Last Update Posted (Estimated)

February 28, 2024

Last Update Submitted That Met QC Criteria

February 26, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • EduStra-HF
  • RCB ID: 2016-A00899-42 (Other Grant/Funding Number: National Drug and Health Products Safety Agency (ANSM))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

Sharing Individual Participant Data requires a specific authorization from the French Board CNIL (Commission Nationale de l'Informatique et des Libertés) which chooses whether to allow the research team to share patient data. A specific request is needed and will be sent to that authority.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Heart Failure

Clinical Trials on Therapeutic education

3
Subscribe